Work

Figure 3 from Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Long-term Safety and Clinical Activity in Patients with Conventional Chondrosarcoma

Year: 2025

Type: other

Abstract: Radiographic images of a patient with conventional CS with PR to ivosidenib at baseline (A) and cycle 55 (B). Imaging of a 38-year-old female with grade 1 conventional CS (involving the right pelvis) previously treated with one systemic therapy, who then received ivosidenib. Coronal fat–suppressed T2-weighted MRI of the pelvis demonstrated a lobular CS in the right ilium and ischium, with relatively uniform hyperintensity, and a lateral extraosseous component at baseline (yellow arrow). After treatment with ivosidenib, there was reconstitution of the fatty marrow signal in the right ilium, with smaller residual islands of T2-hyperintense foci (green arrows) and regression of the extraosseous component. This resulted in a PR that lasted for 25.8 months.

DOI: 10.1158/1078-0432.29221844

Authors: William D. Tap, Gregory M. Cote, Howard Burris, Lia Gore, Anthony Elias, Murali Beeram, Anthony P. Conley, Diego A. Gianolio, Zhe Qu, Susan Pandya, Jonathan C. Trent

Language: English

Topic: Bone Tumor Diagnosis and Treatments

Subfield: Rheumatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4411003408

Cites:

Cited by:

Related to: 10